ReviewJournal of pain research2021
Benefit-Risk Analysis of Buprenorphine for Pain Management.
Review in Journal of pain research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07430345 (Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Strategy for effective analgesia with intravenous buprenorphine in patients with acute postoperative pain.BMC anesthesiology · 2025Pooled it
- A randomized controlled study to compare analgesic efficacy of sublingual buprenorphine and intravenous tramadol in patients undergoing mastectomy.Medical gas researchTrial
- Associations Between Pain Severity and Opioid Agonist Treatment Among People With Drug Injection Experience in Australia.Drug and alcohol review · 2026Article
- Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.Psychopharmacology · 2026Article
- Medicaid Coverage Restrictions and On-Label Buprenorphine Prescribing for Chronic Pain.Journal of general internal medicine · 2026Article
- Perioperative Management of Patients on Buprenorphine.Current pain and headache reports · 2026Review
- Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Flare Reaction Following Intra-articular Steroid Injection in Frozen Shoulder. A Retrospective Study.Journal of research in pharmacy practice · 2026Article
- Intravenous Low-dose Buprenorphine for Acute Pain Management in the Emergency Department: A Case Series.Clinical practice and cases in emergency medicine · 2025Article
- Use of Buprenorphine/Naloxone in an Adult with Cystic Fibrosis.The Canadian journal of hospital pharmacy · 2025Article
- Pharmacological Pain Treatment in Older Persons.Drugs & aging · 2024Review
- Low-Efficacy Mu Opioid Agonists as Candidate Analgesics: Effects of Novel C-9 Substituted Phenylmorphans on Pain-Depressed Behavior in Mice.The Journal of pharmacology and experimental therapeutics · 2024Article
- Article
- Frontline Perspectives on Buprenorphine for the Management of Chronic Pain.Journal of multidisciplinary healthcare · 2024Review
- The Effectiveness of Buprenorphine Transdermal Patch and Low Dose Sublingual Buprenorphine Induction to Transition to Long-Acting Subcutaneous Buprenorphine Injection in Opioid Use Disorder in Inpatient Setting.Kansas journal of medicine · 2024Article
- Development and Validation of a Treatment Algorithm for Osteoarthritis Pain Management in Patients With End-Stage Kidney Disease Undergoing Hemodialysis.Canadian journal of kidney health and disease · 2024Article
- Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.Pain management · 2024Article
- Buprenorphine for Chronic Pain Management: a Narrative Review.Current pain and headache reports · 2023Review
- An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.Acta pharmaceutica Sinica. B · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health care providers in the United States are facing challenges in selecting appropriate medication for patients with acute and chronic pain in the midst of the current opioid crisis and COVID-19 pandemic. When compared with conventional opioids, the partial µ-opioid receptor agonist buprenorphine has unique pharmacologic properties that may be more desirable for pain management. The formulations of buprenorphine approved by the US Food and Drug Administration for pain management include intravenous injection, transdermal patch, and buccal film. A comparison of efficacy and safety data from studies of buprenorphine and conventional opioids suggests that buprenorphine may be a better-tolerated treatment option for many patients that provides similar or superior analgesia. Our benefit-risk assessment in this narrative review suggests that health care providers should consider that buprenorphine may be an appropriate alternative for pain management over other opioids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.